COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. R. [1 ]
Hutton, G. J. [2 ]
Thornton, J. D. [1 ]
Chen, H. [1 ]
Johnson, M. L. [1 ]
Aparasu, R. [1 ]
机构：
[1] Univ Houston, Houston, TX USA
[2] Baylor Coll Med, Med Ctr, McNair Campus, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND104
引用
收藏
页码：S279 / S279
页数：1
相关论文
共 50 条
  • [11] Treatment effectiveness of oral disease-modifying agent in multiple sclerosis adjusting for adherence trajectories
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Aparasu, Rajender R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 18 - 19
  • [12] Fingolimod: an Oral Disease-Modifying Therapy for Relapsing Multiple Sclerosis
    Yeh, E. Ann
    Weinstock-Guttman, B.
    ADVANCES IN THERAPY, 2011, 28 (04) : 270 - 278
  • [13] Improving adherence to injectable disease-modifying drugs in multiple sclerosis
    Bayas, Antonios
    EXPERT OPINION ON DRUG DELIVERY, 2013, 10 (03) : 285 - 287
  • [14] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [15] FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS
    Li, Jieni
    Chikermane, Soumya G.
    Earla, Jagadeswara R.
    Hutton, George J.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [16] Defining non-adherence to the injectable disease-modifying therapies in multiple sclerosis
    McKay, K. A.
    Tremlett, H.
    Patten, S. B.
    Fisk, J. D.
    Evans, C.
    Fiest, K.
    Campbell, T.
    Marrie, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 339 - 340
  • [17] FACTORS ASSOCIATED WITH PRESCRIBING OF ORAL DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS
    Earla, J. R.
    Hutton, G. J.
    Thornton, J. D.
    Aparasu, R. R.
    VALUE IN HEALTH, 2019, 22 : S390 - S390
  • [18] Injectable disease modifying agents in multiple sclerosis: pattern of medication use and clinical effectiveness
    Jarvinen, Elina
    Holmberg, Markus
    Sumelahti, Marja-Liisa
    NEUROLOGY INTERNATIONAL, 2016, 8 (03) : 39 - 41
  • [19] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [20] An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
    Munsell, Michael
    Frean, Molly
    Menzin, Joseph
    Phillips, Amy L.
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 55 - 62
12345